Articles

With companies focusing more and more on orphan diseases and epigenetics growing in popularity, now might be the time where this confluence leads to breakthroughs in rare genetic diseases. We have brought together a list of 5 exciting compounds in various stages of development which are exciting people in the industry. Read more

In an age of personalised medicine and next-gen pharmaceuticals, it is perhaps surprising that antibiotics remain as relevant now as they were at their introduction. Our editor explores some of the news stories about antibiotics so far this year. Read more

This year 2 life science investors made the 2013 Midas List. These investors and many other venture capitalists play an important role in the innovation and successes of biotech SMEs, without which many life saving drugs might not be developed. Here Pharma IQ takes a closer look at their achievements. Read more

The controversy surrounding the impending release of the DSM-5 may have spurred on one of the most interesting developments in psychiatric medicine in decades. Our editor investigates the controversy and asks what's next for the world's most influential diagnostic manual. Read more

Drug design is growing up. Sophisticated, standardised, smart methods of developing new chemical entities (NCEs) are now the order of the day. No Topic shows this better than drug transporter proteins. Read about the latest research on this hot topic. Read more

The old argument of nature vs nurture has been known to be a false dilemma for a long time, the true making of an organism lies in both and no topic illustrates this better than epigenetics. What is epigenetics and why is it important? In this introduction we explore the history and principles of this blossoming field. Read more

Jonas Boström, of AstraZeneca explains how the idea of drug-likeness rules has been controversial ever since Lipinski introduced his rule of five for predicting oral bioavailability 15 years ago. Read more

High-throughput screening (HTS) has developed into a hugely important and valuable area for the pharmaceutical industry, particularly in the field of drug discovery. The method has the potential to reap substantial benefits for the sector in the years to come, provided it receives the necessary support and is helped to grow through efficient practice. Read more

Just how much responsibility should the Pharma and Biotech industry take in the fight against drugs and doping in sport? Read more

The difficulties inherent in drug discovery have led to some interesting new collaborations designed to overcome escalating challenges. The creation of discovery partnerships between pharmaceutical companies and groups such as research organisations, biotech firms and academia is an important part of the industry. Read more

Scepticism comes in many forms, says Lori Lesko, Associate Director of Continuous Improvement at pharmaceutical giant Pfizer. But it can be overcome. In this article Lesko looks at the lessons learned in tackling the challenges of fostering a culture of Continuous Improvement at Pfizer. Read more